From the recently concluded Roth conference investor presentation,
• Phase 1b completion and results due imminently (ahead of recent expectations)
• Lessons from other trials currently running? • In current Phase 1b breast & ovarian cancer trials for PTX-200, interim analysis showed encouraging efficacy
PTX-200 has lots of supportive data and efficacy signals that combine to give confidence leading into the Phase 1b/2 trial.
Sounds like a positive announcement has been signalled...would be very strange if the if all the results were negative.
News: PTX Prescient Therapeutics seeks trading halt, page-3
Add PTX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $32.21M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 25000 | 4.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.0¢ | 29629 | 1 |
View Market Depth
| Last trade - 07.01am 20/11/2024 (20 minute delay) ? |
| PTX (ASX) Chart |
Day chart unavailable
